These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 19146377

  • 21. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
    Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K.
    J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
    [Abstract] [Full Text] [Related]

  • 22. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes.
    Riley RJ, McGinnity DF, Austin RP.
    Drug Metab Dispos; 2005 Sep; 33(9):1304-11. PubMed ID: 15932954
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes.
    Jones HM, Hallifax D, Houston JB.
    Drug Metab Dispos; 2004 May; 32(5):572-80. PubMed ID: 15100181
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development.
    Karlsson FH, Bouchene S, Hilgendorf C, Dolgos H, Peters SA.
    Drug Metab Dispos; 2013 Dec; 41(12):2033-46. PubMed ID: 23918667
    [Abstract] [Full Text] [Related]

  • 29. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C, Reichel A.
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
    Smith DA, Obach RS.
    Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding.
    Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, Okazaki O.
    Drug Metab Dispos; 2009 Sep; 37(9):1970-7. PubMed ID: 19487250
    [Abstract] [Full Text] [Related]

  • 36. In vitro methods in human drug biotransformation research: implications for cancer chemotherapy.
    Hariparsad N, Sane RS, Strom SC, Desai PB.
    Toxicol In Vitro; 2006 Mar; 20(2):135-53. PubMed ID: 16359840
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The prediction of human clearance from hepatic microsomal metabolism data.
    Obach RS.
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):36-44. PubMed ID: 11727321
    [Abstract] [Full Text] [Related]

  • 40. Organ slices for the evaluation of human drug toxicity.
    Vickers AE, Fisher RL.
    Chem Biol Interact; 2004 Nov 01; 150(1):87-96. PubMed ID: 15522263
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.